Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $9.3 million.

  • 4D Molecular Therapeutics' Gains from Investment Securities fell 100.10% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 7.75%. This contributed to the annual value of $9.3 million for FY2024, which is 13.31% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Gains from Investment Securities is $9.3 million, which was up 13.31% from $8.2 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Gains from Investment Securities peaked at $9.3 million during FY2024, and registered a low of $3.2 million during FY2020.
  • In the last 3 years, 4D Molecular Therapeutics' Gains from Investment Securities had a median value of $8.2 million in 2023 and averaged $7.8 million.
  • Data for 4D Molecular Therapeutics' Gains from Investment Securities shows a peak YoY surged of 48.89% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Gains from Investment Securities stood at $3.2 million in 2020, then rose by 21.51% to $3.9 million in 2021, then surged by 48.89% to $5.8 million in 2022, then soared by 42.59% to $8.2 million in 2023, then grew by 13.31% to $9.3 million in 2024.